SiqingFuMD

Oncology • Houston, TX

Physician

Join to view full profile

Are you Dr. Fu?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Unit 0455
Houston, TX 77030
Phone+1 713-792-4318

Fax+1 713-745-3855

Summary

Dr. Siqing Fu, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 2001 - 2004
University of RochesterResidency, Internal Medicine, 1999 - 2001
Yale-New Haven Medical CenterInternship, Internal Medicine, 1998 - 1999
Tongji Medical UniversityClass of 1985

Certifications & Licensure

CA State Medical License 2008 - Present
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TX State Medical License 2005 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
WA State Medical License 2023 - 2025
NY State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Hepatic Arterial Infusion (HAI) of Abraxane Start of enrollment: 2008 Jun 01
Completed
Phase 1
Trientine and Carboplatin in Advanced Malignancies Start of enrollment: 2010 Jul 01
Completed
Phase 1
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide Start of enrollment: 2012 Apr 01
Terminated
Phase 1
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies Start of enrollment: 2011 Apr 20
Completed
Phase 1
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel Start of enrollment: 2012 Jul 01
Completed
Phase 1
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma Start of enrollment: 2012 Sep 01
Completed
Phase 1
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies Start of enrollment: 2014 Jun 27
Completed
Phase 1
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Start of enrollment: 2016 Feb 19
Completed
Phase 1
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Start of enrollment: 2016 Oct 21
Completed
Phase 1
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Start of enrollment: 2016 Dec 01
Completed
Phase 1
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Start of enrollment: 2019 Jan 16
Completed
Phase 2
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2019 Mar 05
Completed
Phase 1
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors Start of enrollment: 2019 Jul 29
Completed
Phase 1
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Start of enrollment: 2022 Feb 09
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Erika P Hamilton, Gerald S Falchook, Judy S Wang, Siqing Fu, Amit M Oza
Targeted Oncology. 2024-11-01
Palbociclib in Patients With Head and Neck Cancer and Other Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer
JCO Precision Oncology. 2024-10-01
Metastatic extraneural glioblastoma diagnosed with molecular testing.
Nazanin K Majd, Henry Hiep Vo, Cesar A Moran, Shiao-Pei Weathers, I-Wen Song
The Oncologist. 2024-09-06

Press Mentions

Personalized Cancer Vaccines Are the Future of Cancer Treatment. Here’s How They WorkAugust 12th, 2024
MD Anderson Research Highlights for December 19, 2022December 19th, 2022
Soricimed Appoints Leading North American Cancer Researcher Dr. Siqing Fu to Its Scientific Advisory BoardDecember 13th, 2022
Join now to see all